Syros Pharmaceuticals Historical PE Ratio image   This SYRS PE ratio history page last updated 3/28/2024
Syros Pharmaceuticals Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q4 2023
3/27/2024
5.84-2.22-8.88NA
Q3 2023
11/14/2023
2.72-1.43-5.72NA
Q2 2023
8/8/2023
3.66-1.30-5.20NA
Q1 2023
5/10/2023
3.43-0.85-3.40NA
Q4 2022
3/2/2023
3.76-0.17-0.68NA
Q3 2022
11/14/2022
3.66-3.21-12.84NA
Q2 2022
8/9/2022
9.27-5.40-21.60NA
Q1 2022
5/16/2022
7.70-4.00-16.00NA
Q4 2021
3/15/2022
11.10-3.80-15.20NA
Q3 2021
11/5/2021
45.60-4.10-16.40NA
Q2 2021
8/5/2021
49.00-3.60-14.40NA
Q1 2021
5/6/2021
55.30-2.30-9.20NA
Q4 2020
3/4/2021
79.60-6.20-24.80NA
Q3 2020
11/5/2020
81.10-4.30-17.20NA
Q2 2020
8/6/2020
120.30-3.80-15.20NA
Q1 2020
5/7/2020
87.70-3.90-15.60NA
Q4 2019
3/5/2020
60.20-4.60-18.40NA
Q3 2019
11/12/2019
50.20-4.70-18.80NA
Q2 2019
8/1/2019
84.80-4.70-18.80NA
Q1 2019
5/1/2019
71.70-4.90-19.60NA
Q4 2018
3/7/2019
69.00-5.40-21.60NA
Q3 2018
11/1/2018
74.10-4.70-18.80NA
Q2 2018
8/7/2018
115.70-4.30-17.20NA
Q1 2018
5/10/2018
115.30-4.80-19.20NA
Q4 2017
3/12/2018
123.20-5.80-23.20NA
Q3 2017
11/8/2017
116.05-5.30-21.20NA
Q2 2017
8/9/2017
228.40-5.20-20.80NA
Q1 2017
5/15/2017
150.10-4.90-19.60NA
Q4 2016
3/20/2017
160.30-4.70-18.80NA
Q3 2016
11/14/2016
127.50-6.50-26.00NA
Q2 2016
8/15/2016
90.00-54.20-216.80NA
Syros Pharmaceuticals PE History Chart
PeriodPriceGAAPTTMPE
Q4 2023
3/27/2024
5.84-2.22-5.80NA
Q3 2023
11/14/2023
2.72-1.43-3.75NA
Q2 2023
8/8/2023
3.66-1.30-5.53NA
Q1 2023
5/10/2023
3.43-0.85-9.63NA
Q4 2022
3/2/2023
3.76-0.17-12.78NA
Q3 2022
11/14/2022
3.66-3.21-16.41NA
Q2 2022
8/9/2022
9.27-5.40-17.30NA
Q1 2022
5/16/2022
7.70-4.00-15.50NA
Q4 2021
3/15/2022
11.10-3.80-13.80NA
Q3 2021
11/5/2021
45.60-4.10-16.20NA
Q2 2021
8/5/2021
49.00-3.60-16.40NA
Q1 2021
5/6/2021
55.30-2.30-16.60NA
Q4 2020
3/4/2021
79.60-6.20-18.20NA
Q3 2020
11/5/2020
81.10-4.30-16.60NA
Q2 2020
8/6/2020
120.30-3.80-17.00NA
Q1 2020
5/7/2020
87.70-3.90-17.90NA
Q4 2019
3/5/2020
60.20-4.60-18.90NA
Q3 2019
11/12/2019
50.20-4.70-19.70NA
Q2 2019
8/1/2019
84.80-4.70-19.70NA
Q1 2019
5/1/2019
71.70-4.90-19.30NA
Q4 2018
3/7/2019
69.00-5.40-19.20NA
Q3 2018
11/1/2018
74.10-4.70-19.60NA
Q2 2018
8/7/2018
115.70-4.30-20.20NA
Q1 2018
5/10/2018
115.30-4.80-21.10NA
Q4 2017
3/12/2018
123.20-5.80-21.20NA
Q3 2017
11/8/2017
116.05-5.30-20.10NA
Q2 2017
8/9/2017
228.40-5.20-21.30NA
Q1 2017
5/15/2017
150.10-4.90-70.30NA
Q4 2016
3/20/2017
160.30-4.70NANA
Q3 2016
11/14/2016
127.50-6.50NANA
Q2 2016
8/15/2016
90.00-54.20NANA
Quotes delayed 20 minutes

Email EnvelopeFree SYRS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Syros Pharmaceuticals (SYRS) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

TALS PE Ratio History
TARA PE Ratio History
TARS PE Ratio History
TBIO PE Ratio History
TCDA PE Ratio History
TCMD PE Ratio History
TCON PE Ratio History
TCRR PE Ratio History
TCRT PE Ratio History
TCRX PE Ratio History
How should the SYRS historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Syros Pharmaceuticals. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this SYRS Historical PE Ratio page.

What is the average historical PE for SYRS based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The SYRS historical PE ratio using the annualized quarterly earnings method works out to NA.

What is the average historical PE for SYRS based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The SYRS historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the Syros Pharmaceuticals Historical PE Ratio information for Syros Pharmaceuticals' stock. The average SYRS historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average SYRS historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this SYRS historical PE result, against the recent PE: when this page was posted on 3/27/2024, the most recent closing price for SYRS had been 5.84, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on SYRS or any other given stock, valuation analysis for SYRS can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Syros Pharmaceuticals PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for SYRS. Thanks for visiting, and the next time you need to research SYRS Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: Funds Holding LXFT, CHK shares outstanding history, AFB Insider Buying.

 

Syros Pharmaceuticals Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2024, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.